Search Results for “research” – Page 279 – media

New AI technology significantly improves human kidney analysis

The ability to quantify the extent of kidney damage and predict the life remaining in the kidney, using an image obtained at the time when a patient visits the hospital for a kidney biopsy, now is possible using a computer model based on artificial intelligence (AI).
- Source: Medical Xpress
- 637
- January 12, 2018
AI kidney Researches
Eisai and Merck Receive Breakthrough Therapy Designation from FDA for LENVIMA® (lenvatinib mesylate) and KEYTRUDA® (pembrolizumab)

Eisai Co., Ltd. and Merck (MRK), known as MSD outside the United States and Canada, announced that they received Breakthrough Therapy Designation from the U.S. Food and Drug Administration (FDA) for Eisai's multiple receptor tyrosine kinase inhibitor LENVIMA® (lenvatinib) in combination with Merck's anti-PD-1 therapy KEYTRUDA® (pembrolizumab) for the potential treatment of patients with advanced and/or metastatic renal cell carcinoma (RCC).
- Source: finance.yahoo
- 534
- January 11, 2018
LENVIMA New Approvals RCC
FDA Accepts New Drug Applications for Merck’s Doravirine

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has accepted for review two New Drug Applications (NDAs) for doravirine, the company’s investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV-1 infection in adults.
- Source: investors.merck
- 512
- January 11, 2018
doravirine NDAs New Approvals NNRTI
Women who work nights face higher cancer risk

Women who regularly work the night shift in Europe and North America may face a 19 percent higher risk of cancer than those who work during the day, said a study Monday.
- Source: msn
- 582
- January 11, 2018
breast cancer cancer Researches
Microsoft Wants to Use Artificial Intelligence to Make CRISPR More Accurate

he gene-editing technology CRISPR could very well one day rid the world of its most devastating diseases, allowing us to simply edit away the genetic code responsible for an illness. One of the things standing in the way of turning that fantasy into reality, though, is the problem of off-target effects. Now Microsoft is hoping to use artificial intelligence to fix this problem.
- Source: GIZMODO
- 419
- January 11, 2018
AI CRISPR Microsoft Researches
Two Former Receptos Execs Launch New San Diego Biotech Startup With $100M

Gossamer Bio is launching with $100 million in seed financing and two biotech heavy hitters as leadership.
- Source: drugdu
- 486
- January 10, 2018
Crohn’s disease Market Views multiple sclerosis Series ulcerative colitis
How doctors and bots can work together

The fear that machines will replace humans in the workplace is not a new one. In 1930, economist John Maynard Keynes conjectured that in the years to come, modern economies would face a new kind of affliction: what Keynes called “technological unemployment.”
- Source: Venturebeat
- 540
- January 10, 2018
AI digital health Market Views
Sangamo and Pfizer announce collaboration for development of zinc finger protein gene therapy for ALS

Sangamo Therapeutics, Inc. and Pfizer Inc. announced a collaboration for the development of a potential gene therapy using zinc finger protein transcription factors to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene.
- Source: Prnewswire
- 448
- January 9, 2018
ALS FTLD Market Views neurodegenerative disease
J&J signs 15 deals for new healthcare solutions

Johnson & Johnson (J&J) has signed 15 new partnerships to explore, develop and advance new medical devices, therapeutics and consumer health solutions.
- Source: Verdict Medical Devices
- 706
- January 9, 2018
AI cancer Company Insight Johnson & Johnson
Addex, Indivior Forge $335M Addiction Disorder Tie-Up

Indivior announced that Indivior UK Limited has entered into a strategic collaboration with Addex Pharma S.A., a wholly-owned subsidiary of Addex Therapeutics (SIX: ADXN) ("Addex"), in the field of GABAB positive allosteric modulators (PAMs). GABAB PAMs have demonstrated preclinical efficacy and tolerability in animal models for alcohol use disorder (AUD) and cocaine use disorder (CUD)1,2.
- Source: Biospace
- 421
- January 8, 2018
AUD CUD GABAB PAM Market Views

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.